PML in a person with multiple sclerosis: Is teriflunomide the felon?

Neurology. 2018 Jan 9;90(2):83-85. doi: 10.1212/WNL.0000000000004804. Epub 2017 Dec 6.

Authors

Lorena Lorefice¹, Giuseppe Fenu², Simonetta Gerevini², Jessica Frau², Giancarlo Coghe², Maria Antonietta Barracciu², Franco Contu², Maria Giovanna Marrosu², Eleonora Cocco²

Affiliations

¹ From University of Cagliari (L.L., G.F., J.F., G.C., M.G.M., E.C.); IRCCS San Raffaele Hospital (S.G.), Milan; and Binaghi Hospital (M.A.B., F.C.), ATS Sardegna, Italy. lorena.lorefice@hotmail.it.
² From University of Cagliari (L.L., G.F., J.F., G.C., M.G.M., E.C.); IRCCS San Raffaele Hospital (S.G.), Milan; and Binaghi Hospital (M.A.B., F.C.), ATS Sardegna, Italy.

PMID: 29212829
DOI: 10.1212/WNL.0000000000004804

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Brain / diagnostic imaging
Crotonates / adverse effects*
Crotonates / therapeutic use
Diagnosis, Differential
Female
Humans
Hydroxybutyrates
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Leukoencephalopathy, Progressive Multifocal / diagnostic imaging
Leukoencephalopathy, Progressive Multifocal / etiology*
Leukoencephalopathy, Progressive Multifocal / therapy
Multiple Sclerosis / complications
Multiple Sclerosis / diagnostic imaging
Multiple Sclerosis / therapy*
Nitriles
Toluidines / adverse effects*
Toluidines / therapeutic use

Substances

Crotonates
Hydroxybutyrates
Immunologic Factors
Nitriles
Toluidines
teriflunomide